Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok, Bart Neyns, Gerald P. Linette et al. · The Lancet Oncology · 2009
Cited by 1,196 works. doi:10.1016/s1470-2045(09)70334-1
Authors
- Jedd D. Wolchok
- Bart Neyns
- Gerald P. Linette
- Sylvie Négrier
- Jose Lutzky
- Luc Thomas
- William C. Waterfield
- Dirk Schadendorf
- Michael Smylie
- Troy H. Guthrie
- Jean‐Jacques Grob
- Jason Alan Chesney
- Kevin M. Chin
- Kun Chen
- Axel Hoos
- Steven J O'Day
- Célèste Lebbé
References
- THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Enhancement of Antitumor Immunity by CTLA-4 Blockade
- A Confidence Interval for the Median Survival Time
- Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
- Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study